HeraMED (ASX:HMD) has announced the success of the first phase of the initial commercial rollout of its strategic partner in the US, e-Lovu Health.

The agreement included 1,000 HeraBEAT smart foetal heart rate monitors and licenses for access and utilisation of the HeraCARE platform for 1,000 pregnancies, with total expected revenues of ~US$550,000.

HeraMED says the majority of these revenues will be reflected in the company’s Q1 2023 Appendix 4C.

It also says that both companies are working together to leverage each other's strengths to grow commercial traction and gain further momentum.